SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
STAMFORD, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference,
Capsida Biotherapeutics to Present at 7th Annual Evercore HealthCONx Conference
Capsida Biotherapeutics ("Capsida"), a leading fully integrated next-generation gene therapy company developing treatments for rare and common diseases across all ages, today announced that the company will present at the 7(th) Annual Evercore HealthCONx Conference being held December 3-5,
Springworks Therapeutics (SWTX) Gets a Buy from Evercore ISI
Springworks Therapeutics (SWTX – Research Report) received a Buy rating and a $60.00 price target from Evercore ISI analyst Cory Kasimov today.
Umoja Biopharma to Present at the 7th Annual Evercore ISI HealthCONx Conference
Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo and off-the-shelf cell therapies that aim to realize the full reach and promise of CAR-T cells, today announced that members of management will participate in a fireside chat and 1x1 investor meetings at the 7th Annual Evercore ISI HealthCONx Conference,
SpringWorks Therapeutics Inc. (SWTX): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts
We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we ...
Vertex leads J.P. Morgan's top biotech picks list for 2025
J.P.  Morgan said its top biotech picks for 2025 were Vertex (NASDAQ:VRTX), Travere (NASDAQ:TVTX), SpringWorks (NASDAQ:SWTX), ...
ETF Daily News20h
Massachusetts Financial Services Co. MA Acquires 108,109 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)
Massachusetts Financial Services Co. MA lifted its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 20.2% during the 3rd quarter, Holdings Channel reports. The ...
Seeking Alpha1d
Finding Winners In Biotech, Probably The Riskiest Sector
Key stocks to watch include Tarsus Pharmaceuticals and SpringWorks Therapeutics, both showing strong potential based on ...
SpringWorks Therapeutics’ mirdametinib shows efficacy in neurofibromatosis study
SpringWorks Therapeutics (SWTX) announced that data from the pivotal, Phase 2b ReNeu trial of mirdametinib, an ...
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Mutual of America Capital Management LLC
Mutual of America Capital Management LLC trimmed its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free ...
Seeking Alpha22d
SpringWorks Therapeutics Merits A Speculative Buy
When we last visited SpringWorks, the company was trying to get its primary drug candidate nirogacestat through the FDA approval process. Nirogacestat is an oral small-molecule gamma-secretase ...
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from ...